Department of Clinical and Community Pharmacy, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Department of Medicine, College of Medicine and Health Sciences, An-Najah National University, Nablus, 44839, Palestine.
Support Care Cancer. 2023 Aug 7;31(9):509. doi: 10.1007/s00520-023-07981-3.
Pain after therapy is an important clinical problem in patients with breast cancer. Unfortunately, cancer patients have a lower quality of life due to inadequate treatment of posttreatment pain; therefore, improving medication management plans and palliative care has become one of the most important targets of cancer therapy. Therefore, the current study aimed to examine the impact of posttreatment pain on medication satisfaction in patients with various stages of breast cancer in Palestine.
A cross-sectional analytical study was conducted et al.-Watani Hospital and An-Najah National University Hospital in the Nablus area. Using the Brief Pain Inventory (BPI), the intensity and interference of pain were evaluated. In addition, patients' satisfaction with cancer management medications was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM).
Two hundred fifty-four patients were included in this study. All were women, with a mean ± SD age of 53.1 ± 10.7 years. The median score for pain severity was 7.0. Pain in the lower extremities was the most reported location. There was a negative association between the global satisfaction domain and the presence of posttreatment pain (p < 0.001). Furthermore, significant differences and negative correlations were found between global satisfaction and posttreatment pain on the day of the interview (p = 0.001), pain medication (p < 0.001), paracetamol use (p < 0.001), and the presence of side effects (p = 0.003). There were significant negative correlations (p < 0.05) between pain severity and interference with effectiveness (r = -0.258, -0.319, respectively), side effects (r = -0.414, -0.514, respectively), convenience (r = -0.274, -0.307, respectively), and global satisfaction domain scores (r = -0.293, -0.287, respectively). Exposure to chemotherapy was the only significant positive correlation with global satisfaction (p = 0.007). The regression analysis results indicated an independent association between chemotherapy use and a higher global satisfaction score (p = 0.011).
Patients with posttreatment pain, side effects, and greater interference of pain with their functioning had lower satisfaction scores. Therefore, better management of their treatment medications, side effects, and pain medications is recommended to enhance their satisfaction and quality of life. Several aspects of palliative care should be organized to improve the patient's satisfaction and quality of life in addition to conducting longitudinal studies to evaluate the pain and satisfaction of different types of cancers.
乳腺癌患者治疗后疼痛是一个重要的临床问题。不幸的是，由于治疗后疼痛处理不当，癌症患者的生活质量较低；因此，改善药物管理计划和姑息治疗已成为癌症治疗的最重要目标之一。因此，目前的研究旨在检查巴勒斯坦不同阶段乳腺癌患者治疗后疼痛对药物满意度的影响。
横断面分析研究在纳布卢斯地区的 Watani 医院和 An-Najah 国立大学医院进行。使用简明疼痛量表（BPI）评估疼痛的强度和干扰。此外，使用治疗满意度问卷（TSQM）评估患者对癌症管理药物的满意度。
本研究纳入了 254 名患者。他们均为女性，平均年龄为 53.1±10.7 岁。疼痛严重程度的中位数评分为 7.0。下肢疼痛是最常见的部位。全球满意度领域与治疗后疼痛之间存在负相关（p<0.001）。此外，在访谈当天，全球满意度与治疗后疼痛之间存在显著差异和负相关（p=0.001），与疼痛药物（p<0.001）、扑热息痛使用（p<0.001）和副作用存在（p=0.003）。疼痛严重程度与有效性（r=-0.258，-0.319）、副作用（r=-0.414，-0.514）、便利性（r=-0.274，-0.307）和全球满意度领域得分之间存在显著负相关（p<0.05）（r=-0.293，-0.287）。化疗暴露是与全球满意度唯一显著正相关的因素（p=0.007）。回归分析结果表明，化疗的使用与更高的全球满意度评分独立相关（p=0.011）。
治疗后疼痛、副作用以及疼痛对功能的干扰较大的患者满意度评分较低。因此，建议更好地管理他们的治疗药物、副作用和疼痛药物，以提高他们的满意度和生活质量。除了进行纵向研究评估不同类型癌症的疼痛和满意度外，还应组织姑息治疗的各个方面，以提高患者的满意度和生活质量。
